Cargando…

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection

BACKGROUND: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Felden, Johann, Schulze, Kornelius, Krech, Till, Ewald, Florian, Nashan, Björn, Pantel, Klaus, Lohse, Ansgar W., Riethdorf, Sabine, Wege, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685725/ https://www.ncbi.nlm.nih.gov/pubmed/29163804 http://dx.doi.org/10.18632/oncotarget.21208

Ejemplares similares

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection
por: von Felden, Johann, et al.
Publicado: (2017)

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
por: Fründt, Thorben, et al.
Publicado: (2022)

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
por: Kocheise, Lorenz, et al.
Publicado: (2023)

Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma
por: von Felden, Johann, et al.
Publicado: (2020)

Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients
por: Fründt, Thorben, et al.
Publicado: (2021)

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation
por: von Felden, Johann, et al.
Publicado: (2016)

Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype
por: Krause, Jenny, et al.
Publicado: (2020)

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
por: Stein, Alexander, et al.
Publicado: (2015)

Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment
por: Fründt, Thorben W., et al.
Publicado: (2022)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations
por: Westphal,, Manfred, et al.
Publicado: (2022)

Case report and literature review: Isolated HCC- recurrence in gallbladder after curative resection
por: Zhang, Shi-Ran, et al.
Publicado: (2023)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Erratum zu: Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
por: von Felden, Johann, et al.
Publicado: (2021)

Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
por: von Felden, Johann, et al.
Publicado: (2021)

Proliferative ductular reactions correlate with hepatic progenitor cell and predict recurrence in HCC patients after curative resection
por: Ye, Fei, et al.
Publicado: (2014)

Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
por: Liu, Gao-Min, et al.
Publicado: (2019)

Impact of low skeletal muscle mass index and perioperative blood transfusion on the prognosis for HCC following curative resection
por: Bekki, Tomoaki, et al.
Publicado: (2020)

Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up!
por: Toubert, Cyprien, et al.
Publicado: (2022)

Inflammation-Related Marker NrLR Predicts Prognosis in AFP-Negative HCC Patients After Curative Resection
por: Wu, Qionglan, et al.
Publicado: (2023)

Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection
por: Tsai, Yu-Chieh, et al.
Publicado: (2021)

Case Report: Solitary metastasis to the appendix after curative treatment of HCC
por: Zhang, Zun-Yi, et al.
Publicado: (2023)

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
por: Knipper, Sophie, et al.
Publicado: (2021)

(18)F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches
por: Kornberg, Arno, et al.
Publicado: (2019)

New foe treated with old guns – supportive role of steroids in the treatment of acute severe hepatitis E
por: Sebode, Marcial, et al.
Publicado: (2014)

Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy
por: Raj, Roma, et al.
Publicado: (2023)

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
por: Paschold, Lisa, et al.
Publicado: (2023)

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch(®) System and the AdnaTest(®)
por: Gorges, Tobias M., et al.
Publicado: (2016)

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy
por: Rink, Michael, et al.
Publicado: (2020)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer
por: Riethdorf, Sabine, et al.
Publicado: (2017)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
por: Bansal, Sanjay, et al.
Publicado: (2021)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC
por: Deshpande, Rahul, et al.
Publicado: (2011)

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
por: Campani, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i29uup2tdq5ps6dng5d8l35kch